EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS

Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent with twice-yearly subcutaneous dosing (after the...

Full description

Saved in:
Bibliographic Details
Main Authors: Lawrence A Leiter (Author), David G Kallend (Author), Wolfgang Koenig (Author), Ulf Landmesser (Author), Kausik K Ray (Author), Gregory G Schwartz (Author), R Scott Wright (Author), YannTong Chiang (Author), Lorena Garcia Conde Orozco (Author), Frederick J Raal (Author)
Format: Book
Published: Elsevier, 2023-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available